Emergent Biosolutions EPS beats by $0.04, misses revenue, revises FY20 guidance

• Emergent Biosolutions (NYSE:EBS): Q3 Non-GAAP EPS of $2.19 beats by $0.04; GAAP EPS of $0.73 misses by $1.03.
• Revenue of $385.2M (+23.5% Y/Y) misses by $53.31M.
• FY2020 guidance: Total revenues of $1,520M-$1,580M from previous guidance of $1,500M-$1,600M vs consensus of $1.52B ; Adjusted net income of $375M-$405M from previous guidance of $340M-$390M; Adjusted EBITDA of $575M-$615M from previous guidance of $535M-$600M.
• Press Release
• https://seekingalpha.com/news/3632865-emergent-biosolutions-eps-beats-0_04-misses-on-revenue-revised-fy20-guidance